HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy

Louise Faaborg; Anders Jakobsen; Marianne Waldstrøm; Christina B. Petersen; Rikke F. Andersen; Karina D. Steffensen

doi:10.2217/bmm-2021-0144

HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy

Louise Faaborg^*, Anders Jakobsen, Marianne Waldstrøm, Christina B. Petersen, Rikke F. Andersen, Karina D. Steffensen

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

35 Downloads (Pure)

Abstract

Aim: In ovarian cancer, methylated HOXA9 (meth-HOXA9) has been proposed as a relevant biomarker, however, its role in the carcinogenic development remains unknown. This study aimed at evaluating meth-HOXA9 as a diagnostic biomarker in ovarian cancer. Materials & methods: The meth-HOXA9 status was examined in 138 tissue specimens encompassing normal ovaries, benign- and borderline tumors, and ovarian cancer using droplet digital PCR. Results: Meth-HOXA9 was detected in 93% (82/88) and 88% (14/16) of ovarian cancer and borderline tumors, respectively. In patients with benign ovarian tumors meth-HOXA9 was detected in 17% (3/18). Using receiver operating characteristic (ROC) analysis meth-HOXA9 had a diagnostic accuracy of 98%. Conclusion: Meth-HOXA9 is highly cancer specific and could serve as a general diagnostic marker of ovarian malignancy.

Original language	English
Journal	Biomarkers in Medicine
Volume	15
Issue number	15
Pages (from-to)	1309-1317
ISSN	1752-0363
DOIs	https://doi.org/10.2217/bmm-2021-0144
Publication status	Published - Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 Louise Faaborg.

Keywords

biomarker
HOXA9
methylation
ovarian cancer
ovarian malignancy
ovarian tumors

Documents & Links

10.2217/bmm-2021-0144Licence: CC BY-NC-ND

Open Access VersionFinal published version, 665 KBLicence: CC BY-NC-ND

1 Ph.D. thesis

Clinical aspects of methylated HOXA9 DNA in ovarian cancer
Faaborg Larsen, L., 24. Jun 2022, Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet. 125 p.
Research output: Thesis › Ph.D. thesis

Open Access
File
111 Downloads (Pure)

Cite this

@article{270b02daae9748e9a81bb958d0146779,

title = "HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy",

abstract = "Aim: In ovarian cancer, methylated HOXA9 (meth-HOXA9) has been proposed as a relevant biomarker, however, its role in the carcinogenic development remains unknown. This study aimed at evaluating meth-HOXA9 as a diagnostic biomarker in ovarian cancer. Materials & methods: The meth-HOXA9 status was examined in 138 tissue specimens encompassing normal ovaries, benign- and borderline tumors, and ovarian cancer using droplet digital PCR. Results: Meth-HOXA9 was detected in 93% (82/88) and 88% (14/16) of ovarian cancer and borderline tumors, respectively. In patients with benign ovarian tumors meth-HOXA9 was detected in 17% (3/18). Using receiver operating characteristic (ROC) analysis meth-HOXA9 had a diagnostic accuracy of 98%. Conclusion: Meth-HOXA9 is highly cancer specific and could serve as a general diagnostic marker of ovarian malignancy. ",

keywords = "biomarker, HOXA9, methylation, ovarian cancer, ovarian malignancy, ovarian tumors",

author = "Louise Faaborg and Anders Jakobsen and Marianne Waldstr{\o}m and Petersen, {Christina B.} and Andersen, {Rikke F.} and Steffensen, {Karina D.}",

note = "Publisher Copyright: {\textcopyright} 2021 Louise Faaborg.",

year = "2021",

month = oct,

doi = "10.2217/bmm-2021-0144",

language = "English",

volume = "15",

pages = "1309--1317",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Future Medicine Ltd.",

number = "15",

}

TY - JOUR

T1 - HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy

AU - Faaborg, Louise

AU - Jakobsen, Anders

AU - Waldstrøm, Marianne

AU - Petersen, Christina B.

AU - Andersen, Rikke F.

AU - Steffensen, Karina D.

PY - 2021/10

Y1 - 2021/10

N2 - Aim: In ovarian cancer, methylated HOXA9 (meth-HOXA9) has been proposed as a relevant biomarker, however, its role in the carcinogenic development remains unknown. This study aimed at evaluating meth-HOXA9 as a diagnostic biomarker in ovarian cancer. Materials & methods: The meth-HOXA9 status was examined in 138 tissue specimens encompassing normal ovaries, benign- and borderline tumors, and ovarian cancer using droplet digital PCR. Results: Meth-HOXA9 was detected in 93% (82/88) and 88% (14/16) of ovarian cancer and borderline tumors, respectively. In patients with benign ovarian tumors meth-HOXA9 was detected in 17% (3/18). Using receiver operating characteristic (ROC) analysis meth-HOXA9 had a diagnostic accuracy of 98%. Conclusion: Meth-HOXA9 is highly cancer specific and could serve as a general diagnostic marker of ovarian malignancy.

AB - Aim: In ovarian cancer, methylated HOXA9 (meth-HOXA9) has been proposed as a relevant biomarker, however, its role in the carcinogenic development remains unknown. This study aimed at evaluating meth-HOXA9 as a diagnostic biomarker in ovarian cancer. Materials & methods: The meth-HOXA9 status was examined in 138 tissue specimens encompassing normal ovaries, benign- and borderline tumors, and ovarian cancer using droplet digital PCR. Results: Meth-HOXA9 was detected in 93% (82/88) and 88% (14/16) of ovarian cancer and borderline tumors, respectively. In patients with benign ovarian tumors meth-HOXA9 was detected in 17% (3/18). Using receiver operating characteristic (ROC) analysis meth-HOXA9 had a diagnostic accuracy of 98%. Conclusion: Meth-HOXA9 is highly cancer specific and could serve as a general diagnostic marker of ovarian malignancy.

KW - biomarker

KW - HOXA9

KW - methylation

KW - ovarian cancer

KW - ovarian malignancy

KW - ovarian tumors

U2 - 10.2217/bmm-2021-0144

DO - 10.2217/bmm-2021-0144

M3 - Journal article

C2 - 34514844

AN - SCOPUS:85116345164

SN - 1752-0363

VL - 15

SP - 1309

EP - 1317

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 15

ER -

HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy

Abstract

Bibliographical note

Keywords

Documents & Links

Fingerprint

Related research output

Clinical aspects of methylated HOXA9 DNA in ovarian cancer

Cite this